AI MARKET SCANNING

BioVie Inc.

AVG HISTORICAL GAP -2.13%
MAX GAP RECORD -9.44%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $BIVI
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 24, 2026 Earnings Release 2026-08-24 (AFTER CLOSE)
-6.54%
Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE)
-1.28%
Aug 14, 2025 Earnings Release 2025-08-14 (AFTER CLOSE)
+3.01%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
-1.74%
Feb 11, 2025 Earnings Release 2025-02-11 (AFTER CLOSE)
-9.44%
May 14, 2024 Earnings Release 2024-05-14 (AFTER CLOSE)
+0.60%
Feb 13, 2024 Earnings Release 2024-02-13 (BEFORE OPEN)
+0.00%
Nov 08, 2023 Earnings Release 2023-11-08 (AFTER CLOSE)
-6.10%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.2%
Bullish Gaps (2)
Bearish Gaps (5)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $BIVI

EXECUTIONS2 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-08-27 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 9m +0.82%
••••-••-•• 🔒 LOCKED ••• x• $•••.•• → $•••.•• ••m +••.••%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗